Rally Retraces Correction Up To Mid-Point YTD Up until this week we have focused on large cap biopharmaceuticals because of revenue momentum, fair valuations and earnings. A risk -off sentiment due to lack of ASCO buzz and the Q1 speculative bubble downdraft has curbed gains. This week with news of the Merck $3.9B deal for […]
High Profile Biotechnology Companies with ASCO Presence Investors and traders waited toward the end of the ASCO Annual Meeting week to buy their favorite stocks. The biotech sector overall was boosted after the close of the meeting after a brief sell-off on June 2 and 3. Most biopharmaceutical stocks peaked in late February so ASCO […]
Update 6/4 Snap- back rally and big green screen! Update 6/3….. Daily Performance-from list below 9 winners, 12 losers Rayno Biopharmaceutical Picks in bold— Winners: AGIO, INCY, SGEN, EPZM, MDVN, IMGN, GILD. CELG, PCYC. Losers: CLVS, ARIA, NLNK,CLDX, BLUE, LBIO, PBYI, KPTI, BMY, AZN, ICPT, XLRN. 30 Day winners: MDVN, PCYC, SGEN —— Rayno Large Cap […]
Rally Developing-Green Screen Alert If you are underweight large cap biotech add FBT ($76.38) up 2%. Most of our large cap picks are up today: ABBV ALXN, BIIB,GILD,REGN. Reverse pattern from tuesday’s downdraft. ————– One of the worse days I have seen in small cap biotech in many months as speculation has ended and investors […]
Volatility Up as ASCO Approaches The ASCO Annual Meeting is not till the end of the month but news regarding abstract titles and clinical data that will be presented at ASCO moved stocks today. Many immuno-oncology stocks have been hard hit in the 2014 sell-off as investors have moved out of small cap speculative growth […]
Update May 30-Fidelity Select Biotech (FBIOX) Fund is lagging Top ETFs FBT and IBB Compared to 2013 when FIDO beat the ETFs it is lagging post February bubble and YTD. It would be difficult to analyze why this happened but my guess is that: FIDO went chasing “bubble” stocks like AEGR, ICPT and was overweight […]
